Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Condition Directory

Alzheimer's Disease clinical trials

Directory of U.S. ClinicalTrials.gov public records for Alzheimer's Disease. Browse Alzheimer's Disease recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced May 20, 2026 Report an issue

ClinicalTrials.gov public records Last synced May 20, 2026, 6:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
20
Shown on this page
12
Local recruiting
8
Local phase groups
4
The trial list below is retrieved from the live ClinicalTrials.gov search API for Alzheimer's Disease. Results on this page are currently sorted by Recently updated.

How Alzheimer's Disease studies are organized in the registry

The registry typically spells this condition “Alzheimer disease” (without the apostrophe-s), and both spellings appear across listings. Early-stage research uses its own vocabulary — prevention and early-intervention studies are often filed under “mild cognitive impairment,” “prodromal,” or “preclinical” rather than the disease name, and some enroll cognitively healthy volunteers at elevated risk. This directory also has a dedicated mild cognitive impairment page.

  • 40% of the 20 locally indexed Alzheimer's Disease records are currently marked recruiting.
  • The most common phase group in the local index is Phase 3 (12 records).
  • The most frequent sponsor is Washington University School of Medicine (6 records).
  • The most listed study location is New Haven, Connecticut (11 records).
Terms that often appear in related listings
mild cognitive impairment early Alzheimer prodromal amyloid

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Alzheimer's Disease. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 1–12 of 20 matching trials for Alzheimer's Disease.
Indexed local directory records.

Phase distribution

Phase 3 12
Phase 2 10
Phase 1 4
Not applicable 2

Top locations

New Haven, Connecticut 11 Atlanta, Georgia 10 St Louis, Missouri 10 Providence, Rhode Island 10 Dallas, Texas 10 Indianapolis, Indiana 8

Top sponsors

Washington University School of Medicine 6 Hoffmann-La Roche 5 Molecular NeuroImaging 2 Novartis Pharmaceuticals 2 Biogen 1 Brigham and Women's Hospital 1

Top therapies

Gantenerumab 3 E2814 2 Lecanemab 2 RO7126209 2 Solanezumab 2 Trontinemab 2

Indexed official records

Open in full search
Recruiting Phase 3 Interventional

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07170150
View directory record Official record
Conditions
Alzheimers Disease
Interventions
Placebo, Trontinemab
Other · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
33
States / cities
Phoenix, Arizona • Imperial, California • Long Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 20, 2026, 12:21 AM EDT
Recruiting Phase 3 Interventional

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

NCT07177352
View directory record Official record
Conditions
Alzheimers Disease
Interventions
No Intervention
Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
13,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 20, 2026, 6:43 AM EDT
Recruiting Phase 3 Interventional

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07169578
View directory record Official record
Conditions
Alzheimers Disease
Interventions
Placebo, Trontinemab
Other · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
33
States / cities
Sun City, Arizona • Irvine, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 20, 2026, 6:43 AM EDT
Recruiting Not applicable Interventional

Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease

NCT06484244
View directory record Official record
Conditions
Alzheimers Disease, Mild Cognitive Impairment
Interventions
5 Sessions of Split-belt Treadmill-based Locomotor Adaptation
Other
Lead sponsor
Emory University
Other
Eligibility
50 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced May 19, 2026, 7:04 PM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

NCT06647498
View directory record Official record
Conditions
Alzheimers Disease, Alzheimers Disease, Familial, Dementia
Interventions
Matching Placebo (Remternetug), Remternetug
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2034
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced May 20, 2026, 6:43 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

NCT05552157
View directory record Official record
Conditions
Alzheimers Disease, Alzheimers Disease, Familial, Dementia
Interventions
Matching Placebo (Remternetug), Remternetug (SC)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2034
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced May 20, 2026, 6:43 AM EDT
Recruiting Phase 2 Interventional

Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease

NCT06489548
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions
Foralumab TZLS-401 100 µg, Foralumab TZLS-401 50 µg
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
60 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced May 19, 2026, 9:19 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

University of Central Florida Music Study

NCT07306065
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Dementia Alzheimer Type
Interventions
Music intervention
Other
Lead sponsor
University of Central Florida
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced May 16, 2026, 11:27 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

NCT04639050
View directory record Official record
Conditions
Alzheimers Disease
Interventions
Placebo, RO7126209
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
17
States / cities
Atlantis, Florida • Clermont, Florida • Lady Lake, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced May 19, 2026, 7:52 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

NCT05269394
View directory record Official record
Conditions
Alzheimers Disease, Alzheimers Disease, Familial, Dementia
Interventions
E2814, Lecanemab, Matching Placebo (E2814)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced May 20, 2026, 6:43 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

NCT01760005
View directory record Official record
Conditions
Alzheimers Disease, Alzheimers Disease, Familial, Dementia
Interventions
E2814, Gantenerumab, Lecanemab, Matching Placebo (E2814), Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), Solanezumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
490 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced May 20, 2026, 6:43 AM EDT
Completed Phase 3 Interventional Results available

A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease

NCT05891496
View directory record Official record
Conditions
Alzheimers Disease
Interventions
Placebo, Semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
55 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Sun City, Arizona • Delray Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced May 18, 2026, 6:21 AM EDT

About this Alzheimer's Disease clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Alzheimer's Disease as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Alzheimer's Disease.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Alzheimer's Disease.